Clincosm LogoSign in Get a demo

Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence

Sponsor
Peking University Third Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT04566471
Collaborator
(none)
200
Enrollment
120
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical features of patients, through taking into account of the research status of palmoplantar pustulosis and generalized pustular psoriasis and the characteristics of medical insurance data.

Condition or Disease Intervention/Treatment Phase
  • Other: prevalence/incidence

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
Actual Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
PPP and GPP

Palmoplantar pustulosis (PPP) and Generalized pustular psoriasis (GPP) are rare chronic inflammatory skin diseases, characterized by repeated episodes of sterile pustules in several months or years, associated with erythrokeratodermia generally. Both two diseases are easy to cause skin rupture, leading to bleeding and pain.

Other: prevalence/incidence
It is an observational study for prevalence/incidence, no intervention provided.

Outcome Measures

Primary Outcome Measures

  1. prevalence of Palmoplantar pustulosis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease

  2. prevalence of Generalized pustular psoriasis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease

Secondary Outcome Measures

  1. incidence of Palmoplantar pustulosis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease

  2. incidence of Generalized pustular psoriasis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Epidemiological characteristics of diseases: Mainly referring to indicators that could reflect the frequency related to the disease

  3. Economic burden of Palmoplantar pustulosis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Mainly referring to the consumption of medical resources, including medical expenses of patients.

  4. Economic burden of Generalized pustular psoriasis [From 2012 to 2016 in the Urban Employee Basic Medical Insurance (UEBMI) data of China]

    Mainly referring to the consumption of medical resources, including medical expenses of patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • The insured population of the national urban employee basic medical insurance and the urban resident basic medical insurance from January 1, 2012, to December 31, 2016 (60 months) (the denominator)

  • The patients have been diagnosed with palmoplantar pustulosis or generalized pustular psoriasis (including disease name, English abbreviation and ICD code)

  • Both outpatient and inpatient patients are included

Exclusion Criteria:

  • The individuals whose information is only contained in the reimbursement settlement database but not in the insurance coverage database will be considered as invalid reimbursement individuals and be excluded from the study (the denominator)

  • The patients have been diagnosed with non-PPP and -GPP diseases, such as pustular psoriasis in palm and toe, pustular arthritis osteitis and SAPHO syndrome

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Principal Investigator: Siyan Zhan, PhD, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT04566471
Other Study ID Numbers:
  • BI13680065
First Posted:
Sep 28, 2020
Last Update Posted:
Sep 28, 2020
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking University Third Hospital
Generalized pustular psoriasis
Palmoplantar pustulosis
Urban Employee Basic Medical Insurance (UEBMI) data
prevalence
incidence
Additional relevant MeSH terms:
Psoriasis

Study Results

No Results Posted as of Sep 28, 2020